SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Jon Koplik who wrote (2510)11/19/2001 8:34:46 PM
From: Savant  Respond to of 3576
 
Very positive. "only one of the nine GRN163-treated mice had a tumor that reached critical size. In all of the mice that received GRN163, tumor growth was slowed. In some cases, tumor growth was essentially blocked and in one case, the tumor completely disappeared. The brain cancer used for the studies was selected because it is a particularly aggressive
form of cancer and is resistant to current chemotherapy and radiotherapy approaches"


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News